Telo Historical Cash Flow

Stocks . Canada . 
Stock . Telo Genomics Corp
TELO Stock  CAD 0.12  0.01  7.69%   
Analysis of Telo Genomics cash flow over time is an excellent tool to project Telo Genomics Corp future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as End Period Cash Flow of 3.2 M or Depreciation of 53.5 K as it is a great indicator of Telo Genomics ability to facilitate future growth, repay debt on time or pay out dividends.
   Cash Flow   Balance Sheet   Income Statement
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Telo Genomics Corp latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Telo Genomics Corp is a good buy for the upcoming year.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telo Genomics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

About Telo Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Telo balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Telo's non-liquid assets can be easily converted into cash.
Balance Sheet
Statement
Details
Profit & Loss
Statement
Details
Financial
Indicators
Details
Valuation
Indicators
Details

Telo Genomics Cash Flow Chart

At this time, Telo Genomics' Stock Based Compensation is fairly stable compared to the past year. Begin Period Cash Flow is likely to climb to about 3.3 M in 2024, whereas Free Cash Flow is likely to drop (2.6 M) in 2024.
Stock Based Compensation  End Period Cash Flow  
Add Fundamental

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.
Most accounts from Telo Genomics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Telo Genomics Corp current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telo Genomics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
At this time, Telo Genomics' Stock Based Compensation is fairly stable compared to the past year. Begin Period Cash Flow is likely to climb to about 3.3 M in 2024, whereas Free Cash Flow is likely to drop (2.6 M) in 2024.

Telo Genomics cash flow statement Correlations

Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Capital Expenditures
Net Income
End Period Cash Flow
Net Borrowings
Depreciation
Change To Account Receivables
Change To Operating Activities
Change To Netincome
Change To Liabilities
Investments
Other Non Cash Items
Change In Cash
0.02-0.08-0.54-0.390.19-0.030.29-0.19-0.04-0.58-0.450.23-0.210.020.01
Stock Based Compensation
0.02-0.17-0.46-0.30.5-0.16-0.3-0.13-0.02-0.46-0.440.490.31-0.540.57
Free Cash Flow
-0.08-0.170.48-0.2-0.850.99-0.270.4-0.660.330.43-0.810.58-0.050.15
Change In Working Capital
-0.54-0.460.480.19-0.720.41-0.180.470.080.960.98-0.750.010.41-0.39
Begin Period Cash Flow
-0.39-0.3-0.20.19-0.09-0.150.77-0.53-0.030.240.15-0.28-0.280.31-0.55
Capital Expenditures
0.190.5-0.85-0.72-0.09-0.840.04-0.420.48-0.63-0.690.95-0.17-0.280.25
Net Income
-0.03-0.160.990.41-0.15-0.84-0.170.32-0.730.250.36-0.810.58-0.080.15
End Period Cash Flow
0.29-0.3-0.27-0.180.770.04-0.17-0.68-0.06-0.15-0.17-0.14-0.430.33-0.57
Net Borrowings
-0.19-0.130.40.47-0.53-0.420.32-0.680.210.490.5-0.28-0.040.33-0.12
Depreciation
-0.04-0.02-0.660.08-0.030.48-0.73-0.060.210.220.110.47-0.580.53-0.44
Change To Account Receivables
-0.58-0.460.330.960.24-0.630.25-0.150.490.220.97-0.66-0.180.49-0.47
Change To Operating Activities
-0.45-0.440.430.980.15-0.690.36-0.170.50.110.97-0.73-0.110.41-0.4
Change To Netincome
0.230.49-0.81-0.75-0.280.95-0.81-0.14-0.280.47-0.66-0.73-0.17-0.310.35
Change To Liabilities
-0.210.310.580.01-0.28-0.170.58-0.43-0.04-0.58-0.18-0.11-0.17-0.610.69
Investments
0.02-0.54-0.050.410.31-0.28-0.080.330.330.530.490.41-0.31-0.61-0.93
Other Non Cash Items
0.010.570.15-0.39-0.550.250.15-0.57-0.12-0.44-0.47-0.40.350.69-0.93
Click cells to compare fundamentals

Telo Genomics Account Relationship Matchups

High Positive Relationship

Net Income
+ 0.99
Free Cash Flow
Change To Operating Activities
+ 0.98
Change In Working Capital
Change To Operating Activities
+ 0.97
Change To Account Receivables
Change To Account Receivables
+ 0.96
Change In Working Capital
Change To Netincome
+ 0.95
Capital Expenditures
End Period Cash Flow
+ 0.77
Begin Period Cash Flow

High Negative Relationship

Other Non Cash Items
- 0.93
Investments
Capital Expenditures
- 0.85
Free Cash Flow
Net Income
- 0.84
Capital Expenditures
Change To Netincome
- 0.81
Net Income
Change To Netincome
- 0.81
Free Cash Flow
Change To Netincome
- 0.75
Change In Working Capital

Telo Genomics cash flow statement Accounts

201920202021202220232024 (projected)
Change In Cash901.5K2.7M(943.5K)(19.7K)(22.7K)(21.5K)
Stock Based Compensation359.5K141.6K151.4K160.2K144.2K228.5K
Free Cash Flow(1.1M)(1.1M)(1.8M)(2.7M)(2.4M)(2.6M)
Change In Working Capital(206.4K)(51.1K)107.1K(2.1K)(2.4K)(2.3K)
Begin Period Cash Flow19.5K921.0K3.6M2.7M3.1M3.3M
Other Cashflows From Financing Activities644.2K1.8M681.6K(147.5K)(169.6K)(161.1K)
Total Cash From Operating Activities(1.1M)(1.1M)(1.8M)(2.6M)(2.4M)(2.5M)
Net Income(1.2M)(1.1M)(2.1M)(2.8M)(2.5M)(2.7M)
Total Cash From Financing Activities2.0M3.8M876.6K2.7M3.1M2.4M
End Period Cash Flow921.0K3.6M2.7M2.7M3.1M3.2M
Depreciation64.7K62.2K57.0K33.1K29.8K53.5K
Change To Account Receivables(12.7K)(47.5K)58.8K(25.8K)(29.7K)(28.2K)
Change To Operating Activities32.2K(40.2K)39.5K(28.1K)(32.3K)(30.7K)
Change To Netincome343.4K263.8K(45.7K)151.4K136.3K129.5K
Change To Liabilities284.0K(153.5K)(43.2K)76.4K68.8K76.3K
Investments(8.7K)(9.3K)(25.2K)(69.1K)(79.4K)(83.4K)
Other Non Cash Items(95.7K)(183.5K)206.6K252.2K227.0K274.4K
Issuance Of Capital Stock1.7M2.1M195K2.8M3.3M3.4M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Telo Stock Analysis

When running Telo Genomics' price analysis, check to measure Telo Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telo Genomics is operating at the current time. Most of Telo Genomics' value examination focuses on studying past and present price action to predict the probability of Telo Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telo Genomics' price. Additionally, you may evaluate how the addition of Telo Genomics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY